Valuation: GSK plc

Market Cap 79.93B 106B 93.31B 87.09B 150B 10,171B 153B 1,033B 404B 5,033B 399B 390B 17,399B P/E 2026 *
13.2x
P/E 2027 * 11.7x
Enterprise Value 96.87B 129B 113B 106B 181B 12,326B 186B 1,252B 489B 6,100B 483B 473B 21,086B EV / Sales 2026 *
2.85x
EV / Sales 2027 * 2.61x
Free-Float
99.07%
Yield 2026 *
3.47%
Yield 2027 * 3.64%
1 day-1.83%
1 week+1.22%
Current month+3.82%
1 month+2.94%
3 months-3.71%
6 months+0.81%
Current year+6.00%
1 week 26
Extreme 26
27
1 month 25.31
Extreme 25.312
27.04
Current year 22.75
Extreme 22.75
31.48
1 year 17.72
Extreme 17.72
31.48
3 years 15.54
Extreme 15.54
31.48
5 years 13.48
Extreme 13.48
31.48
10 years 13.48
Extreme 13.48
31.48
Manager TitleAgeSince
Chief Executive Officer - 01/01/2026
Director of Finance/CFO 64 01/05/2023
Chief Tech/Sci/R&D Officer - 01/12/2021
Director TitleAgeSince
Director/Board Member - 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 68 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.83%+1.22% - - 106B
-0.87%+4.04%+58.60%+163.92% 1,079B
-0.45%+3.87%+57.95%+52.18% 640B
+0.04%+3.95%+37.69%+74.54% 465B
-1.82%+1.29%+36.36%+30.82% 353B
-1.49%+0.02%+34.37%+40.20% 301B
-2.31%+0.71%+11.13%+14.23% 271B
-1.41%+3.90%+2.40%-39.06% 228B
-1.39%+5.90%+27.70%+64.00% 209B
-1.18%+1.83%+16.20%+72.69% 165B
Average -1.24%+4.83%+31.38%+52.61% 412.19B
Weighted average by Cap. -1.18%+4.86%+41.25%+77.70%

Financials

2026 *2027 *
Net sales 33.99B 45.16B 39.68B 37.04B 63.63B 4,325B 65.2B 439B 172B 2,140B 170B 166B 7,399B 35.62B 47.33B 41.58B 38.82B 66.68B 4,533B 68.33B 460B 180B 2,243B 178B 174B 7,754B
Net income 6.14B 8.15B 7.17B 6.69B 11.49B 781B 11.77B 79.32B 31.02B 387B 30.62B 29.95B 1,336B 6.96B 9.24B 8.12B 7.58B 13.03B 885B 13.35B 89.91B 35.16B 438B 34.71B 33.95B 1,515B
Net Debt 16.94B 22.5B 19.77B 18.46B 31.71B 2,155B 32.49B 219B 85.59B 1,067B 84.49B 82.65B 3,687B 13.16B 17.49B 15.36B 14.34B 24.64B 1,675B 25.25B 170B 66.51B 829B 65.65B 64.22B 2,865B
Logo GSK plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
66,841
Date Price Change Volume
29/07/26 $26.08 -1.83% 504
28/07/26 $26.56 +0.23% 500
27/07/26 $26.50 +4.69% 550
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
20.07GBP
Average target price
21.42GBP
Spread / Average Target
+6.70%

Quarterly revenue - Rate of surprise